• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Alkeus Pharmaceuticals

News headline image
Alkeus Pharmaceuticals Appoints Renowned Retina Specialist and Biotech Executive Carlos Quezada-Ruiz, M.D., F.A.S.R.S., as Chief Medical Officer
December 02, 2025
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Announces Presentation of Gildeuretinol Data at the American Academy of Ophthalmology (AAO) 2025 Annual Meeting, October 18-21 in Orlando
October 09, 2025
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Announces Presentation of Positive Interim TEASE-3 Study Data in Early-Stage Stargardt Disease Patients Treated with Oral Gildeuretinol
August 07, 2025
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Announces Gildeuretinol Data Presentations During the American Society of Retina Specialists (ASRS) 43rd Annual Meeting July 29-August 2
July 23, 2025
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Presents Gildeuretinol Data During the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025
May 07, 2025
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Announces Presentations of Gildeuretinol Data During the Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025
April 24, 2025
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Announces Establishment of Scientific Advisory Board
February 25, 2025
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Announces Two Presentations of Oral Gildeuretinol Data During the 48th Annual Meeting of the Macula Society Being Held February 12-15, 2025
February 11, 2025
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Announces New Positive Interim TEASE-3 Study Results Showing Gildeuretinol Prevented Disease Progression in Early-Stage Stargardt Patients
January 09, 2025
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 07, 2025
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Announces Positive Gildeuretinol Data Will Be Presented During the 12th International FLORetina ICOOR Congress December 5–8 in Florence, Italy
December 05, 2024
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Receives FDA Rare Pediatric Disease and Fast Track Designations for Gildeuretinol as a Treatment for Stargardt Disease
November 18, 2024
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Appoints David Arkowitz as Chief Financial Officer
October 31, 2024
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Topline Results from Alkeus Pharmaceuticals’ Study of Oral Gildeuretinol Demonstrate Significant Trend in Slowing GA Progression and Visual Function Improvement
October 23, 2024
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Announces Data Presentations at the American Academy of Ophthalmology (AAO) 2024 Annual Meeting, October 18-21 in Chicago
October 17, 2024
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Announces Results from the SAGA Study of Oral Gildeuretinol in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
September 17, 2024
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Announces Presentation of a TEASE-3 Study Update Showing Progression Stalled in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol
July 18, 2024
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Appoints Tamara Dillon as Chief Human Resources Officer
July 16, 2024
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Accomplished Biotech Leader Michel Dahan Joins Alkeus as President and CEO
July 02, 2024
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Appoints Eric L. Trachtenberg as Chief Legal Officer
May 29, 2024
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progression in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol
May 08, 2024
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Patients During the ARVO 2024 Annual Meeting May 5-9
May 01, 2024
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Appoints Seemi Khan, M.D., Chief Medical Officer
January 23, 2024
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Presents Positive Interim Data Showing Gildeuretinol Halted Stargardt Disease Progression
January 10, 2024
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Jan. 10, 2024
December 21, 2023
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Pharmaceuticals Presents Positive Gildeuretinol Trial Results at American Academy of Ophthalmology, Demonstrating Significant Slowing of Retinal Atrophic Lesions in Stargardt Disease
November 03, 2023
From Alkeus Pharmaceuticals
Via GlobeNewswire
News headline image
Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path for gildeuretinol (ALK-001) in the Treatment of Stargardt Disease
June 05, 2023
From Alkeus Pharmaceuticals
Via GlobeNewswire
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap